Will operate as a separate company of Johnson & Johnson headed by Dennis Longstreet as president. The operation was previously a division of the J&J subsidiary, Ortho Pharmaceutical. Longstreet has been president of the division since early 1986. Ortho Biotech markets Orthoclone OKT-3 for reverse acute kidney transplantation rejection in the U.S. and sells Eprex (EPO) through J&J subsidiaries in 36 countries outside the U.S.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.